logo
Share SHARE
FONT-SIZE Plus   Neg

SolarCity Posts Loss; Stock Tumbles

SolarCity Corp. (SCTY), a provider of solar energy systems, said Wednesday it slipped to a loss for the fourth quarter, hurt by increased expenses that offset growth in revenues.

The California-based company reported fourth-quarter net loss to stockholders of $3 million, compared with net income of $14 million last year.

On a per share basis, net loss to common shareholders for the quarter was $1.10, compared with net income of $0.24 in the prior year.

SolarCity, which made its debut on the Nasdaq last December, said revenues for the quarter rose to $25.3 million from $20.7 million a year ago.

Analysts polled by Thomson Reuters estimated a loss of $0.44 per share on revenues of $36.67 million for the quarter. Analysts' estimates typically exclude special items.

The company's results were mainly impacted by operating expenses that spiked to $37.9 million from $22.3 million in the prior year.

SolarCity's operating activities include collecting energy contract payments, acquiring new customers, operating solar energy systems, among others. During the quarter, the company deployed 48 MW, an increase of 129% from the prior year, while total customers nearly tripled to 8,557.

SolarCity closed Wednesday at $19.27, up 3.88%, on a volume of 0.7 million shares on the Nasdaq. In after hours, the stock dropped $2.02 or 10.48%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of International Consolidated Airlines Group S.A. were gaining around 3 percent in London trading after the airline reported Friday higher profit in its second quarter, benefited by higher passenger revenues, despite weak cargo revenues. The company now expects low double digit percentage growth in pre-exceptional operating profit in 2016. Swiss banking giant UBS Group AG reported Friday a 14 percent decline in second quarter profit with weakness in net interest income. Looking ahead, the company said the difficult conditions continue to persist, yet the firm is well positioned to benefit from even a moderate improvement in conditions. UBS shares were gaining around 3 percent in the morning trading in Zurich. We are well into the third quarter and past the middle of the year and it is time to take stock of regulatory decisions awaiting some biotech stocks in August. Despite the uncertain macroeconomic environment, the markets have run up, with the S&P 500 Index making new highs session after session. Valuation concerns may keep traders at bay. However, the biotech space is a different cup of tea.
comments powered by Disqus
Follow RTT